Cell Signaling Technology

Product Pathways - MAPK Signaling

SignalSlide® Phospho-p44/42 MAPK (Thr202/Tyr204) IHC Controls #8103

Protocols

Custom Ordering Details

Sections are cut freshly upon ordering. Domestic: Please allow up to three business days for your order to be processed and shipped. International: Please allow up to one week for your order to be processed and shipped.

Description

Each control slide contains formalin fixed, paraffin-embedded NIH/3T3 cells, treated with either U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene) #9903 or TPA (12-O-Tetradecanoylphorbol-13-Acetate) #4174 , that serve as a control for phospho-p44/42 MAPK (Thr202/Tyr204) immunostaining. U0126 has been shown to be a highly selective inhibitor of MEK1 and MEK2. TPA induces phosphorylation of p44/42 MAPK. Western blot analysis was performed on extracts derived from the same cells to verify the efficacy of the U0126 and TPA treatments.

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded NIH/3T3 cells, treated with U0126 #9903 (left) or TPA #4174 (right), using Phospho-p44/42MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb #4370.

Schematic

Schematic

Applications

These slides are intended for use in immunohistochemical assays. Please see the Companion Products for a list of prodcucts that can be used with these slides.

Companion Products

Background

Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs, such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3), and research investigators consider it an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family, as well as Mos and Tpl2/COT. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors, such as U0126 and PD98059.

  1. Roux, P.P. and Blenis, J. (2004) Microbiol Mol Biol Rev 68, 320-44.
  2. Baccarini, M. (2005) FEBS Lett 579, 3271-7.
  3. Meloche, S. and Pouysségur, J. (2007) Oncogene 26, 3227-39.
  4. Roberts, P.J. and Der, C.J. (2007) Oncogene 26, 3291-310.
  5. Rubinfeld, H. and Seger, R. (2005) Mol Biotechnol 31, 151-74.
  6. Murphy, L.O. and Blenis, J. (2006) Trends Biochem Sci 31, 268-75.
  7. Dalby, K.N. et al. (1998) J Biol Chem 273, 1496-505.
  8. Marais, R. et al. (1993) Cell 73, 381-93.
  9. Kortenjann, M. et al. (1994) Mol Cell Biol 14, 4815-24.
  10. Owens, D.M. and Keyse, S.M. (2007) Oncogene 26, 3203-13.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!


For Research Use Only. Not For Use In Diagnostic Procedures.

Products